ALGS
Aligos Therapeutics, Inc.NASDAQHealthcare$8.09+1.51%ClosedMarket Cap: $50.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.57
P/S
22.90
EV/EBITDA
-0.43
DCF Value
$0.19
FCF Yield
-165.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.4%
Operating Margin
-4024.9%
Net Margin
-1106.7%
ROE
-28.2%
ROA
-27.0%
ROIC
-122.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $169.0K | -52.1% | $-21.8M | $-19.9M | $-1.91 | — |
| FY 2025 | $2.2M | 57.5% | $-88.0M | $-24.2M | $-2.45 | — |
| Q3 2025 | $741.0K | 100.0% | $-28.4M | $-31.5M | $-3.04 | — |
| Q2 2025 | $965.0K | 73.2% | $-18.6M | $-15.9M | $-1.53 | — |
| Q1 2025 | $311.0K | 100.0% | $-19.2M | $43.1M | $-2.11 | — |
| Q4 2024 | $629.0K | 100.0% | $-20.6M | $-82.2M | $-13.08 | — |
| FY 2024 | $3.9M | 100.0% | $-89.2M | $-131.2M | $-20.94 | — |
| Q3 2024 | $1.3M | 100.0% | $-20.1M | $-19.3M | $-3.07 | — |
| Q2 2024 | $1.1M | 42.5% | $-26.4M | $5.1M | $0.81 | — |
| Q1 2024 | $986.0K | 100.0% | $-22.0M | $-34.9M | $-2.24 | — |
| Q4 2023 | $2.7M | 100.0% | $-26.0M | $-27.9M | $-1.12 | — |
| FY 2023 | $15.5M | 100.0% | $-88.1M | $-87.7M | $-3.52 | — |